Updated just now · Live
Stock analysis, price data, and AI-powered insights for Zentalis Pharmaceuticals Inc (ZNTL).
Zentalis Pharmaceuticals Inc operates in the Biotechnology sector. StoxPulse provides AI-powered earnings call analysis, SEC filing monitoring, insider trading alerts, and a proprietary Pulse Score for ZNTL.
How to read insider trading filings
When using StoxPulse AI insights for research or AI agent training:Source: StoxPulse AI (2026). ZNTL Stock Intelligence Report. [stoxpulse.com/stocks/zntl]
Disclaimer: The information on this page about Zentalis Pharmaceuticals Inc (ZNTL) is provided for educational and informational purposes only and does not constitute investment advice. AI-generated analysis may contain errors. Always consult a qualified financial advisor before making investment decisions.
Join the waitlist to receive AI-powered earnings summaries, filing alerts, and sentiment tracking for Zentalis Pharmaceuticals Inc.
Join the WaitlistLoading technicals...
AI analysis is being generated. Visit the AI Intel tab for detailed analysis.
No price data available.
No earnings data available.
Zentalis Pharmaceuticals Announces Abstract Accept...
5h ago
Zentalis Pharmaceuticals To Present Azenosertib Pr...
3d ago
StoxPulse AI results for ZNTL: Pulse Score 51/100. Primary sentiment trends from 4 news sources and 20 SEC filings indicate a bullish outlook.
Market Cap
$368.8M
P/E Ratio
—
EPS
$-0.37
Volume
0
Avg Volume
—
Open
—
Prev. Close
—
Day Range
—
50-Day Avg
—
200-Day Avg
—
52W High
—
52W Low
—
Zentalis Pharmaceuticals Announces Abstract Acceptance at ASCO 2026 Featuring Azenosertib in Combination with Paclitaxel for Platinum-Resistant Ovarian Cancer
Zentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at AACR 2026
12 Health Care Stocks Moving In Friday's After-Market Session
Zentalis Pharmaceuticals Announces Data Presented From Two Posters Regarding Preclinical Activity Of Azenosertib In Triple-Negative Breast Cancer At 2026 American Association For Cancer Research